# NCT07185997 (NCT07185997)

> Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07185997
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ArriVent BioPharma, Inc.
- Conditions: Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer; EGFR P-Loop and Alpha C-Helix Compressing; EGFR PACC; EGFR Uncommon Mutations
- Interventions: Firmonertinib; EGFR-TKI inhibitor based on investigator's choice
- Enrollment: 480
- Primary outcome: Progression Free Survival (PFS) determined by blinded independent central review (BICR)
- Primary outcome: Confirmed overall response rate (ORR) as determined by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 17
- YouTube: 3
- Podcasts: 2
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct07185997

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07185997", "email": "<work email>"}; the inbox owner confirms by the emailed link.